A drug, usually used for curing gout has been found to be helpful in stabilizing the health of a kidney disease patient. It has been concluded in a study, which found that allopurinol treatment given to patients with chronic kidney disease lowers the inflammation and reduces the pace of kidney disease.

It was also revealed that the treatment also lessens the risk of cardiovascular disorder and the chances of hospitalization also drops.

Basically, Allopurinol is a drug used for treatment of patients having surplus uric acid in their blood or hyperuricemia, which can cause gout and sometimes it can also lead to the kidney failure. Due to increased levels of uric acid, patients are also at a higher risk of budding hypertension and heart disease.

Also, the patients with CKD have hyperuricemia, but these patients have not yet been tested for the advantages of this drug.

This was stated after Marian Goicoechea, Jose Luno, form Hospital General Universitario Gregorio Marañon, in Madrid, Spain, with their team observed 113 CKD patients. They were divided into two groups where one group was given allopurinol 100 mg every day and others were given their usual therapy.

Then the team observed kidney disease succession, cardiovascular events including heart attacks and hospitalizations among patients. This evaluation was done for two years.

It was then found that Allopurinol treatment delayed the kidney disease progression and the risk of cardiovascular problems 71% and the hospitalizations risk was reduced 62%.